Every Form 4 that CME Group Inc. (CME) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CME filings page.
CME Group Inc. director Martin J. Gepsman sold 400 shares of Class A common stock on October 22, 2026, at $302.50 per share. The sale was reported as a direct transaction, leaving him with 25,244 shares. The transaction description identifies it as a sale in the open market or a private transaction; no Rule 10b5-1 plan is reported.
CME Group Inc. director William R. Shepard reported that his revocable living trust acquired 293 shares at $268.76 per share on September 25, 2026, through a broker-administered dividend reinvestment plan. On August 18, 2026, a 2,554-share transfer changed the form of beneficial ownership from direct to indirect via the trust; direct holdings after the transfer were 1,067 shares.
CME GROUP INC. (CME) reported that Julie Winkler, Sr MD Chief Commercial Officer, received an equity award and related tax withholdings in Common Stock Class A.
On September 15, 2026, she acquired 2,864 shares as a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, 2026, a total of 1,413 shares were surrendered to the issuer to satisfy tax withholding obligations in connection with vesting of previously granted restricted stock. No Rule 10b5-1 trading plan is reported.
CME GROUP INC. (CME) reported that Chief Transformation Officer Ken Vroman received an equity compensation award and related tax-withholding share dispositions. On September 15, 2026, he was granted 2,592 shares of Class A common stock as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. In connection with the vesting of previously granted restricted stock, a total of 1,211 shares of Class A common stock were surrendered to CME Group to satisfy tax withholding obligations on September 15 and 16, 2026. No Rule 10b5-1 trading plan is reported for these transactions.
CME GROUP INC. reported that Jack J. Tobin, its Managing Director and Chief Accounting Officer, received a grant of 700 shares of Class A common stock on September 15, 2026 at $275.09 per share as restricted stock under the CME Group Omnibus Stock Plan. In connection with vesting of previously granted restricted stock, a total of 347 shares of Class A common stock were surrendered to CME Group to satisfy tax withholding obligations on September 15 and 16, 2026 at per-share prices of $275.09 and $272.46, respectively. No Rule 10b5-1 trading plan is reported for these transactions.
CME GROUP INC. (CME) reported that officer Suzanne Sprague, COO & Global Head of Clearing, received an award of 2,864 shares of Class A common stock on September 15, 2026 as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.
On September 15, 2026 and September 16, 2026, a total of 1,152 shares of Class A common stock were surrendered to CME Group Inc. to satisfy tax withholding obligations related to the vesting of previously granted restricted stock. These transactions were reported as direct ownership and were not made under a Rule 10b5-1 trading plan.
CME GROUP INC. (CME) reported insider equity activity by Derek Sammann, Sr MD Global Head of Commodities Markets. On September 15, 2026, he received 2,864 shares of Class A common stock as a restricted stock grant at $275.09 per share under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, 2026, a total of 1,413 shares were surrendered to CME at prices of $275.09 and $272.46 per share to satisfy tax withholding obligations upon vesting of previously granted restricted stock. On May 25, 2026, 4,629 shares were moved from direct ownership into the reporting person’s revocable living trust and reported as an indirect holding, a change in the form of beneficial ownership that the company states is exempt from Section 16 under Rule 16a-13. As of September 15, 2026, 7,022 shares were also held indirectly by the reporting person’s spouse. No Rule 10b5-1 trading plan is reported for these transactions.
CME GROUP INC. (CME) reported that Timothy Francis McCourt, Sr MD Global Head Equity & FX, received an award of 2,592 shares of Class A common stock on September 15, 2026 as a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments subject to continued service. In connection with the vesting of previously granted restricted stock, a total of 1,334 shares were surrendered to the issuer on September 15–16, 2026 to satisfy tax withholding obligations, at reference prices of $275.09 and $272.46 per share. No Rule 10b5-1 trading plan is reported for these transactions.
CME GROUP INC. (CME) reported that Senior Managing Director and General Counsel John Clifford Marchese received an award of 784 shares of Class A common stock on September 15, 2026 under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, 2026, a total of 241 shares were surrendered back to CME Group at prices around $272–$275 per share to satisfy tax withholding obligations related to the vesting of previously granted restricted stock. No Rule 10b5-1 trading plan is reported, and the filing notes that a separate promotion-related equity grant is expected in March 2027 and would be reported in a later Form 4.
CME GROUP INC. (CME) reported insider equity activity by President and CFO Lynne Fitzpatrick. On September 15, 2026, she received a grant of 4,088 shares of Class A common stock as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, 2026, a total of 1,340 shares were surrendered to the issuer to satisfy tax withholding obligations upon vesting of previously granted restricted stock, at reference prices of $275.09 and $272.46 per share; no Rule 10b5-1 trading plan is reported.
CME GROUP INC. (symbol: CME) is the issuer of record for a Form 4 filing submitted to the SEC. DUFFY TERRENCE A reported acquisition or exercise transactions in this Form 4 filing.
CME GROUP INC. (CME) reported that Chairman and CEO Terrence A. Duffy received an equity compensation grant of 21,812 shares of Class A common stock on September 15, 2026. The award is restricted stock under the CME Group Omnibus Stock Plan and vests in four equal annual installments, subject to continued service. Following this grant, he directly holds 62,442 shares of Class A common stock. No Rule 10b5-1 trading plan is reported for this award.
CME GROUP INC. (CME) reported that Michael G. Dennis, Global Head of Fixed Income, received a grant of 2,592 shares of Class A common stock on September 15, 2026 as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, 2026, 274 shares were surrendered on each date (a total of 548 shares) to CME Group to satisfy tax withholding obligations in connection with vesting of previously granted restricted stock. The filing also reports 40.81 shares of Class A common stock held indirectly by his spouse.
CME GROUP INC. (CME) reported that Chief Information Officer Sunil Cutinho received a grant of 2,864 shares of Class A common stock on September 15, 2026 as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, he surrendered a total of 1,413 shares to CME Group to satisfy tax withholding obligations related to the vesting of previously granted restricted stock.
CME GROUP INC. (CME) director Elizabeth A. Cook reported the sale of 500 shares of Class A common stock on September 14, 2026 at $280.11 per share through an entity described as a trust. Following this transaction, the trust holds 17,916 shares, and a separate joint account is reported holding 20 shares, both as indirect ownership. No Rule 10b5-1 trading plan is reported for these transactions.
CME GROUP INC. (CME) disclosed that Chairman and CEO Terrence A. Duffy sold a total of 15,000 shares of Class A common stock on September 10, 2026 in open-market or private transactions. The filing states these sales were not made under a Rule 10b5-1 trading plan and reports no post-transaction share balance.
Tierney Robert J JR reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Robert J. Tierney Jr. received a grant of 645 shares of Class A common stock on June 25, 2026. The shares were valued at $225.00 per share for reporting purposes and were issued as part of the company’s annual equity compensation program for non-employee directors.
The award consists of fully vested shares under the CME Group Director Stock Plan and is not subject to any vesting conditions, meaning Tierney has full ownership upon grant. Following this equity grant, he directly holds 14,345 shares of CME Group Class A common stock.
GEPSMAN MARTIN J reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Martin J. Gepsman received a grant of 645 shares of Class A common stock on June 25, 2026. The shares were issued at an indicated value of $225.00 per share as part of the company’s annual equity compensation program for non-employee directors.
After this award, Gepsman directly holds 25,644 Class A shares. According to the disclosure, the granted shares are fully vested upon issuance and are not subject to any vesting conditions, highlighting that this is a compensation-related equity grant rather than an open-market purchase.
CME Group Inc. director William R. Shepard increased his stake in the company through a mix of market purchases and stock awards. On June 25, 2026, he made open-market purchases totaling 339.0999 shares of Class A common stock at $230.57 per share, including shares held indirectly through a trust.
On the same date he also acquired 1,067.0000 shares at a reference price of $225.00 per share through fully vested equity awards, shares taken in lieu of cash board retainers, and a dividend reinvestment plan under CME’s non‑employee director programs. Following these transactions, holdings reported include 260,442.3220 shares indirectly by trust and 3,620.7680 shares directly, indicating these moves are small relative to his overall position and largely compensation related.
Seifu Rahael reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Seifu Rahael received a grant of 645 shares of Class A common stock on June 25, 2026. The shares were issued at a value of $225.00 per share as part of the company’s annual equity compensation program for non-employee directors.
The footnote explains these are fully vested shares under the CME Group Director Stock Plan and are not subject to any vesting conditions. Following this award, Rahael directly holds 4,739 Class A shares, reflecting routine, compensation-related equity rather than an open-market purchase.
Suskind Dennis reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Dennis Suskind received a grant of 645 shares of Class A Common Stock on June 25, 2026 as equity compensation. The shares were valued at $225.00 per share for reporting purposes and were issued under the CME Group Director Stock Plan.
These shares are fully vested and not subject to any vesting conditions, meaning Suskind has immediate rights to them. Following this grant, he directly holds a total of 3,344 shares of CME Group Class A Common Stock. This is a routine, compensation-related award rather than an open-market purchase or sale.
SIEGEL HOWARD J reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Howard J. Siegel reported stock awards of Class A Common Stock as part of his non-employee director compensation. On June 25, 2026, he received 422 shares at $225 per share as a fully vested annual equity grant under the CME Group Director Stock Plan.
On the same date, he also received 645 fully vested shares at $225 per share, issued at his election in lieu of all or part of his annual cash retainer, with the share count based on the closing price on the grant date. Separately, the filing shows 21,873 shares of Class A Common Stock held indirectly by a trust.
Mulchrone Patrick J reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Patrick J. Mulchrone received a grant of 645 shares of Class A common stock as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. The grant price was $225.00 per share, and the shares are fully vested with no vesting conditions. After this award, he directly holds 29,130 Class A shares and has an additional 25,000 shares reported as indirectly owned by his spouse.
Maloney Patrick W reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Patrick W. Maloney received a grant of 645 fully vested shares of Class A common stock at $225 per share. The award was issued as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. Following this grant, Maloney directly holds 4,743 shares of Class A common stock.
Lucas Deborah J reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Deborah J. Lucas received an equity award of Class A common stock. She was granted 645 fully vested shares at a price of $225 per share as part of CME Group’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. Following this grant, she directly holds 4,533 Class A shares. This is a compensation-related stock award, not an open-market purchase.
Lockett Phyllis M reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Phyllis M. Lockett received an equity award of 645 shares of Class A common stock on June 25, 2026. The award was granted at $225.00 per share as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.
These shares are fully vested and not subject to any vesting conditions, meaning Lockett has immediate ownership rights. Following this grant, she directly holds 4,285 shares of CME Group Class A common stock, reflecting routine, compensation-related share ownership rather than an open-market purchase or sale.
Kaye Daniel G reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Daniel G. Kaye received a grant of 645 shares of Class A common stock on June 25, 2026. The award was issued at $225.00 per share as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.
These shares are fully vested and not subject to any further vesting conditions. Following this grant, Kaye directly holds 4,845 Class A common shares, reflecting routine stock-based compensation rather than an open-market purchase.
Hobert William W reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director William W. Hobert reported routine equity compensation grants and an internal ownership reclassification, with no open‑market trades. On June 25, 2026, he received two Class A Common Stock awards: 422 shares as a fully vested annual equity grant and 645 shares issued at $225 per share in lieu of part of his cash retainer.
On May 1, 2026, WH Trading LLC made a pro‑rata, in‑kind distribution of 20,320 shares of Class A Common Stock to Hobert for no consideration, moving those shares from indirect to direct ownership. A separate 20.531‑share adjustment corrected prior clerical tracking errors so reported beneficial ownership aligns with actual holdings.
CME Group Inc. director Harold Eugene Ford Jr. reported receiving equity-based compensation in the form of Class A common stock. On June 25, 2026, he was granted 422 fully vested shares at $225 per share under the CME Group Director Stock Plan, as part of the annual equity compensation program for non-employee directors. On the same date, he also acquired 645 shares issued in lieu of a portion of his annual cash retainer, with the share count determined by dividing the cash retainer by the closing price on the grant date. These are compensation-related share awards, not open-market purchases or sales.
Durkin Bryan T reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Bryan T. Durkin received an equity award of 645 shares of Class A Common Stock at $225.00 per share. The shares were granted as part of CME Group’s annual equity compensation program for non-employee directors and are fully vested with no further vesting conditions. Following this grant, Durkin directly holds 43,652 Class A shares.
Cook Elizabeth A reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Elizabeth A. Cook reported an equity compensation grant and updated indirect holdings of Class A common stock. She received 645 fully vested shares of Class A common stock, issued as part of CME Group's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan, at a value of $225 per share. After this grant, an indirectly held trust account holds 18,416 shares of Class A common stock. A separate indirect holding entry shows 20 shares of Class A common stock held through a joint account.
Carey Charles P reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Charles P. Carey reported new indirect holdings of Class A common stock through trust-related awards and other entities. On June 25, 2026, a trust associated with him received 422 shares at $225 per share and another 645 shares at the same price.
Footnotes explain that 422 shares were granted as fully vested stock under the company’s annual equity compensation program for non-employee directors, and 645 shares were issued instead of part of his annual cash retainer, based on the closing share price on the grant date.
After these awards, indirect holdings shown include 6,846 shares by trust, 6,424 shares by another trust entry, 185 shares held by a firm, and a small partnership interest of 0.375 share, all reported as indirect ownership.
Bitsberger Timothy S. reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Timothy S. Bitsberger received a grant of 645 shares of Class A Common Stock valued at $225 per share. This was issued as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.
Following this award, Bitsberger directly holds 11,766 shares of CME Group Class A Common Stock. The granted shares are fully vested and are not subject to any vesting conditions, meaning he has full ownership and control of them immediately.
Benesh Kathryn reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Kathryn Benesh received an equity award of 645 shares of Class A common stock at $225.00 per share. The shares were granted as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan and are fully vested with no further vesting conditions. Following this grant, she holds a total of 2,751.948 Class A shares directly.
CME Group Inc. senior managing director and Chief HR Officer Hilda Harris Piell reported an open-market sale of 5,753 shares of Class A common stock at an average price of $304.63 per share. Following this transaction, she directly holds 27,702 shares of CME Group stock.
CME Group Inc. Chairman and CEO Terrence A. Duffy reported selling a total of 35,000 shares of Class A common stock in open-market transactions on May 15, 2026. The sales occurred in two blocks: 9,004 shares at a weighted average price of $299.58 per share and 25,996 shares at a weighted average price of $298.14 per share.
According to the footnotes, each reported price is a weighted average for multiple trades, with actual sale prices ranging from $298.00 to $298.89 for one block and $299.00 to $299.95 for the other. The filing indicates these were standard open-market sales of non-derivative common stock.
CME Group Inc. director William R. Shepard reported buying a net 1,469.84 shares of Class A common stock at $297.38 per share. The purchases on March 26, 2026 included 1,407.78 shares acquired indirectly through a trust and 62.06 shares acquired in his direct account.
The indirectly held shares rose to 260,117.54 held by a trust, while directly held shares increased to 2,539.45. A footnote explains that the acquired shares reflect a dividend reinvestment plan administered by his broker, meaning cash dividends were automatically used to buy additional CME shares.
CME Group Inc. senior managing director and general counsel Jonathan L. Marcus reported an open-market sale of 3,291 shares of Class A common stock on March 17, 2026 at $313.37 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he now holds 7,192 shares directly. This Form 4/A amendment only corrects the reported sale price; all other details from the original Form 4 remain the same.
CME Group Inc. senior managing director and general counsel Jonathan L. Marcus reported an open-market sale of 3,291 shares of Class A common stock at $333.37 per share. After this transaction, he directly holds 7,192 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 18, 2025, indicating it was scheduled in advance rather than timed discretionarily.
CME Group Inc. senior managing director Timothy Francis McCourt reported equity compensation activity involving Class A common stock. He received a grant or award of 5,504 shares at a reference price of $311.40 per share tied to performance share vesting from a 2022 award. In related non-market transactions, he surrendered 2,810 shares and separately 94 shares back to the company to cover tax withholding obligations on the performance share award and restricted stock vesting. After these transactions, he holds 12,108 shares of CME Group Class A common stock directly.
CME Group Inc. senior managing director and general counsel Jonathan L. Marcus received an equity award of 5,270 shares of Class A common stock on March 15, 2026. The vesting amount was based on CME’s total shareholder return versus the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025.
On the same date, Marcus surrendered 2,377 shares to the company to cover tax withholding on the performance share award and 261 shares to cover taxes on restricted stock vesting. These tax-withholding dispositions were not open-market sales. After these transactions, he directly holds 10,483 CME Class A shares.
CME Group Sr MD & Chief HR Officer Hilda Harris Piell reported compensation-related share activity. She received 7,076 shares of Class A common stock as a grant tied to performance shares awarded in 2022 under CME Group's Omnibus Stock Plan, based on total shareholder return relative to the S&P 500 over a three-year period ending December 31, 2025. To cover tax withholding on this award, she surrendered 3,039 shares back to the company. After these transactions, she directly holds 33,455 shares of CME Group Class A common stock.
CME Group COO & Global Head of Clearing Suzanne Sprague received 5,504 shares of Class A common stock as a performance share award. The vested shares were granted under CME Group's Omnibus Stock Plan and were based on the company's total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025.
To cover tax withholding obligations tied to this vesting and to separate restricted stock vesting on March 15, 2026, she surrendered a total of 2,515 shares back to the company. After these compensation-related and tax-withholding entries, she directly holds 13,836 shares of CME Group Class A common stock.
CME Group Chairman and CEO Terrence A. Duffy reported the vesting of 62,902 shares of Class A common stock on March 15, 2026. These performance shares were granted in 2022 and vested based on CME Group’s total shareholder return versus the S&P 500 over the period from January 1, 2023 through December 31, 2025.
To cover related tax withholding obligations, Duffy surrendered 27,866 shares back to the company at a reference price of $311.40 per share. After these compensation-related transactions, he directly holds 90,630 shares of CME Group Class A common stock, reflecting a routine equity award and associated tax withholding rather than open-market buying or selling.
CME Group Inc. Chief Transformation Officer Ken Vroman reported routine equity compensation activity. He acquired 7,076 shares of Class A common stock valued at $311.40 per share through the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan.
On the same date, 3,135 shares at $311.40 per share were surrendered back to the company to cover tax withholding obligations related to this award, rather than sold on the open market. Following these transactions, Vroman directly holds 18,851 shares of CME Group Class A common stock.
CME Group Inc. senior managing director and Chief Commercial Officer Julie Winkler reported compensation-related share activity. She acquired 8,256 shares of Class A common stock at $311.40 per share through the vesting of performance shares granted in 2022, based on total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025. To cover tax withholding obligations from this award, she surrendered 3,658 shares back to the company, resulting in a net increase of 4,598 shares and direct ownership of 30,110 shares after the transactions.
CME Group senior executive Derek Sammann received a stock award and surrendered shares for taxes. On March 15, 2026, he acquired 8,256 shares of Class A common stock at $311.40 per share from the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan.
The number of vested shares was based on total shareholder return versus the S&P 500 from January 1, 2023 through December 31, 2025. On the same date, 3,627 shares at $311.40 were surrendered back to the company to cover tax withholding, leaving 13,312 shares held directly. The filing also shows 11,028 shares held indirectly by a trust and 7,022 shares held indirectly by a spouse.
CME Group Inc. President and CFO Lynne Fitzpatrick reported equity compensation activity in the form of vested stock awards. She acquired 5,504 shares of Class A common stock valued at $311.40 per share from performance shares granted in 2022 and earned based on total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025.
Fitzpatrick then surrendered 2,439 shares to the company to satisfy tax withholding obligations on this performance share award and another 76 shares to cover taxes on restricted stock vesting on March 15, 2026. These tax-withholding dispositions were not open-market sales. After these transactions, she directly owned 23,913 shares of CME Group Class A common stock.
CME Group Inc. reported that MD and Chief Accounting Officer Jack J. Tobin received a grant of 608 shares of Class A common stock as a vested performance share award, valued at $311.40 per share. The award reflects performance shares granted in 2022, determined by CME’s total shareholder return versus the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025. To cover related tax withholding obligations, Tobin surrendered 179 shares back to the company. After these compensation-related transactions, he directly holds 25,409 Class A shares.
CME Group Inc. Chief Information Officer Sunil Cutinho reported routine equity compensation activity. On March 15, 2026, 8,256 shares of Class A common stock vested from a performance share award granted in 2022 under CME Group’s Omnibus Stock Plan at a reference price of $311.40 per share.
The vesting was based on the company’s total shareholder return relative to the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025. To satisfy tax withholding obligations related to the award, 3,658 shares were surrendered back to the company at the same price, leaving Cutinho with 23,586 directly held shares after these transactions.
CME Group Inc. managing director and chief accounting officer Jack J. Tobin made a bona fide gift of 105 shares of Class A common stock on March 11, 2026. After this charitable transfer, he continues to hold 24,980 shares directly, indicating the gift represents a small portion of his stake.